Klebsiella pneumoniae Isolate for Research and Diagnostic Development
This technology includes Klebsiella pneumoniae isolate to be used for research studies and diagnostic tests to detect antimicrobial resistance.
Cell Line for Adult T-cell Leukemia with Stable Co-expression of CD4 and CD8 for the Development of Therapeutics
This technology includes a cell line of Adult T-cell Leukemia (ATL) which contains a full-length copy of the HTLV-I genome and dually expressed CD4 and CD8, which can be used for developing therapeutics against HIV and other diseases which may involve interaction with dual-positive T-cells. This cell line can also be used to study the regulation of various cellular genes by HTLV-I since it contains a single integrated copy of the virus expressing all of the viral gene products.
NeoExpansion – A Method to Identify and Selectively Expand Neoantigen-specific T Cells, Including T Cell Receptor-engineered T Cells and Tumor Infiltrating Lymphocytes
Summary:
The National Cancer Institute (NCI) seeks co-development partners and/or licensees for a method of identifying and selectively expanding neoantigen-specific T cells.
Small Molecule Anti-cancer Agents that Stabilize the MYC-G-Quadruplex
The proto-oncogene c-Myc is deregulated and overexpressed in ~70% of all cancers. Thus, c-Myc is an attractive therapeutic target since disrupting c-Myc activity could be used as pan-chemotherapy. Beyond cancer, Myc is also a positive effector of tissue inflammation, and its function has been implicated in the pathophysiology of heart failure. Because c-Myc is a transcription factor, a rationally designed small molecule targeting c-Myc would be required to exhibit significant specificity.